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	 Recently,	there	has	been	more	interest	with	antidiabetic	agents	commencing	natural	products
from	plants	as	a	better	treatment	than	currently	used	synthetic	drugs.	The	high	performance
liquid	 chromatography	 analysis	 of	 methanolic	 Acalypha	wilkesiana	 leaves	 extract	 revealed
occurrence	 of	 twenty	 one	 polyphenolic	 compounds.	 Catechin	 is	 the	 main	 constituent
(29.91%),	followed	by	apigenin	(20.96%),	then,	ellagic	acid,	quercetin,	kampferol,	ferulic	acid,
luteolin,	pyrogallol,	rutin,	caffeic	acid,	chlorogenic	acid,	protocatechouic	acid,	p‐coumaric	acid,
caffiene,	syrigic	acid,	catechol	and	p‐OH‐benzoic	acid	in	percentages	of	17.54,	10.45,	7.63,	4.67,
4.61,	 4.30,	 3.21,	 3.15,	 2.10,	 1.48,	 1.43,	 1.13,	 1.09,	 1.08	 and	 1.05%,	 respectively.	 The
antidiabetic	and	heamatological	effects	of	methanolic	Acalypha	wilkesiana	leaves	extract	(10,
20	 and	 40	 mg/100	 g	 body	 weight)	 in	 streptozotocin	 diabetic	 rats	 were	 investigated
comparing	with	metformin	HCl	(50	mg/100	g	body	weight)	for	30	days.	Our	results	indicated
that	the	most	effective	dose	of	methanolic	Acalypha	wilkesiana	leaves	extract	was	40	mg/100
g	 body	 weight,	 which	 decreased	 blood	 glucose	 level	 to	 about	 77.37%	 in	 diabetic	 rats,
compared	 with	 a	 percentage	 of	 76.50%	 achieved	 by	 administration	 with	 metformin	 HCl.
Furthermore,	 liver	 functions	activity,	kidney	 functions,	 lipid	profile,	 atherogenic	 indices	and
haematological	parameters	were	scrutinized	in	diabetic	rats	treated	with	methanolic	Acalypha
wilkesiana	leaves	extract.	These	results	indicate	that	the	methanolic	leaves	extract	of	Acalypha
wilkesiana,	have	favorable	effects	in	bringing	down	the	severity	of	diabetes	and	justify	its	use
in	traditional	medicine	for	the	treatment	of	diabetes	and	its	complications.	
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1.	Introduction	
	
Diabetes	 mellitus	 is	 a	 group	 of	 metabolic	 diseases	
characterized	by	chronic	hyperglycemia	and	disturbances	in	fat	
and	protein	metabolism	due	 to	deficiency	 of	 insulin	 secretion	
and/or	 action	 [1].	 In	 addition	 to	 hyperglycemia,	 diabetes	
mellitus	 leads	 to	 long	 term	 multi‐organ	 complications	 and	
causes	damage	to	eye,	heart,	kidneys,	nerves	system	and	blood	
vessels	 [2].	 Streptozotocin	 (STZ),	 an	 antibiotic	 produced	 by	
Streptomyces	achromogenes,	 is	 the	most	widely	 used	 agent	 in	
experimental	 diabetes	 [3].	 The	 main	 cause	 of	 streptozotocin	
induced	 β‐cell	 death	 in	 the	 alkylation	 of	 DNA	 by	 nitrosourea	
moiety	 of	 this	 compound.	 However,	 reduction	 of	 nitric	 oxide	
and	 reactive	 oxygen	 species	 may	 also	 be	 involved	 in	 DNA	
fragmentation	 and	 other	 deleterious	 effect	 of	 streptozotocin	
such	 as	 increasing	 in	 serum	 level	 of	 lipid	 peroxide	 due	 to	
oxidation	of	cells	[4].	
Though	 different	 types	 of	 oral	 hypoglycemic	 agents	 are	
available	along	with	insulin	for	the	treatment	of	diabetes,	there	
is	an	 increase	demand	by	patients	to	use	the	natural	products	
with	 anti‐diabetic	 activity	 [5].	 Herbal	 products	 can	 improve	
glucose	 metabolism	 and	 the	 overall	 condition	 of	 individuals	
with	 diabetes,	 not	 only	 by	 hypoglycemic	 effects,	 but	 also	 by	
improving	 lipid	 metabolism,	 antioxidant	 status	 and	 capillary	
function	 [6].	 Acalypha	 wilkesiana	 is	 one	 of	 a	 number	 of	
medicinal	herbs	that	have	potential	for	use	in	the	management	
of	 diabetes	 mellitus.	 It	 is	 a	 member	 of	 the	 spurge	 family	
Euphorbiaceae	 and	belongs	 to	 the	genus	Acalypha,	 comprising	
about	 570	 species.	 The	 plant	 has	wide	 uses	 in	 the	 traditional	
medicines	 for	 the	 treatment	 of	 bacterial	 and	 fungal	 skin	
infections,	neonatal	jaundice,	and	gastrointestinal	disorders	[7].	
Acalypha	wilkesiana	has	been	reported	to	possess	antimicrobial	
[8],	antihypertension	[9]	and	anticarcinogenic	properties	 [10].	
It	has	also	been	reported	by	Udobang	et	al.,	[11]	that	the	crude	
leaf	extracts	and	fractions	of	this	plant	exhibit	antiparasitic	and	
analgesic	properties.	Though	this	plant	is	not	edible,	it	is	found	
to	 contain	 alkaloids,	 tannins	 and	 resins	 [12].	 The	 chemical	
constituents	 of	 Acalypha	 wilkesiana	 leaves	 included	 acaly‐
phamide,	 aurantiamide,	 succinimide	 calypho‐lactate,	 2‐methyl	
anthraquinone,	 tri‐o‐methyl	 ellagic	 acid,	 β‐sitosterol	 and	 β‐D‐
glucoside	 [13].	 Four	 kaempferol	 glycosides	 namely:	
mauritianin,	 clitorin,	 nicotiflorin	 and	 biorobin	 have	 also	 been	
isolated	 from	 the	 flowers	 and	 leaves	 of	 Acalypha	 wilkesiana	
[14].	Not	much	pharmacological	research	has	been	carried	out	
on	 this	 plant	 despite	 its	 importance	 in	 traditional	 medicine.	
Therefore,	 the	aim	of	this	study	is	to	examine	the	efficiency	of	
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methanolic	 leaves	 extract	 of	 Acalypha	 wilkesiana	 as	
hypoglycemic	 agent	 and	 some	 blood	 constituents	within	 STZ‐
induced	diabetic	rats.		
	
2.	Experimental	
	
2.1.	Materials	
	
The	 present	 investigation	was	 carried	 out	 using	Acalypha	
wilkesiana	leaves	belong	to	family	Euphorbiaceae.	The	samples	
collected	 from	 the	 experimental	 farm	 of	 the	 Faculty	 of	
Agriculture,	 Mansoura	 University,	 Mansoura,	 Egypt	 (April,	
2013).	 Streptozotocin	 and	 methanol	 were	 purchased	 from	
Sigma	 Chemical	 Co.	 (St.	 Louis,	 MO,	 USA),	 while	 metformin	
hydrochloride	 was	 obtained	 from	 Chemical	 Industries	
Development	 (CID)	 for	pharmaceutical	 industries,	Giza,	Egypt.	
All	 other	 chemicals	were	 of	 the	 highest	 available	 commercial	
grade.	
	
2.2.	Methods	
	
2.2.1.	Preparation	of	methanolic	Acalypha	wilkesiana	leaves	
extract	
	
Acalypha	wilkesiana	leaves	samples	were	air	dried	in	the	shade	
and	 ground	 into	 a	 fine	 powder,	 containing	 11.65%	moisture.	
Powdered	air	dried	leaves	(1	Kg)	were	extracted	by	soaking	at	
room	 temperature	 for	 six	 times	 with	 methanol	 (20	 L).	 The	
methanolic	 extract	 was	 filtrated	 using	 Whatman	 filter	 paper	
(No.	1)	and	then	concentrated	to	nearly	dryness	under	reduced	
pressure	by	using	the	rotary	evaporator	at	45	°C	to	achieve	the	
crude	 methanolic	 extract	 which	 kept	 at	 4	 °C	 for	 further	
investigation	and	the	percentage	yield	of	the	extract	was	4.54%	
(w:v).	
	
2.2.2.	Analysis	of	polyphenols	by	HPLC	technique	
	
Phenolic	 compounds	 of	 A.	wilkesiana	 leaves	 extract	 were	
identified	 and	 quantified	 at	 the	 Central	 laboratory,	 National	
Research	 Center,	 Giza,	 Egypt,	 according	 to	 the	 method	
described	 by	 Goupy	 et	 al.,	 [15]	 using	 reversed	 phase	 high	
performance	 liquid	 chromatography	 (RP‐HPLC)	 with	 direct	
injection.	 Detection	 and	 quantification	 were	 performed	 with	
the	help	of	 the	 isocratic	Varian	system,	equipped	with	Alltima	
column	5mm	(C18,	Hypersil	MOS,	5	μm,	200	×	2.1	mm,	Hewlett	
Packard)	 4.6	 ×	 250	 mm	 and	 a	 detector	 namely	 Photo	 Diode	
Array	(PDA)	type.	A	gradient	elution	was	employed	using	two	
solvent	systems.	Solvent	A	consisted	of:	acetic:water	(2:98,	v:v),	
solvent	B:	acetonitrile:water	(70:30,	v:v)	with	1%	of	formic	acid	
(v:v).	 The	 solvent	 flow	 rate	 was	 1	 mL/min,	 volume	 of	 the	
injected	sample	was	10	μL	and	separation	was	performed	at	35	
°C.	 The	 amounts	 of	 phenolic	 compounds	 in	 the	 extract	 were	
assayed	 by	 external	 calibration	 curves,	 comparing	 their	
retention	times	with	known	standards	(caffeic	acid,	p‐coumaric	
acid,	 catechin	 and	 quercetin).	 For	 example,	 100	 mg	 standard	
quercetin	was	taken	into	100	mL	volumetric	flask,	dissolved	in	
the	 mobile	 phase	 and	 make	 up	 to	 the	 mark.	 The	 flask	 was	
shaken	for	10	min	and	the	volume	was	made	up	to	the	mark	to	
obtain	a	standard	stock	solution	of	quercetin	(1000	μg/mL).	A	
stock	solution	was	 filtered	 through	a	0.1	μm	membrane	 filter,	
and	 then	 the	 10	 ppm	working	 standard	 solution	 of	 quercetin	
was	prepared.	Suitable	aliquots	of	stock	solution	were	pipette	
out	 and	 volumes	were	made	 up	 to	 the	mark	with	 the	mobile	
phase.	To	prepare	a	stock	solution	of	sample,	1	g	of	accurately	
weighed	 methanolic	 Acalypha	 wilkesiana	 leaves	 extract	 were	
taken	 in	 a	 100	 mL	 volumetric	 flask,	 dissolved	 in	 the	 mobile	
phase	and	made	up	to	the	mark.	After	setting	the	instrument	10	
μL	 of	 standard	 solution	 was	 injected	 and	 chromatogram	
recorded.	 From	 this,	 the	 area	 of	 chromatogram	 and	 the	
percentage	of	quercetin	content	were	calculated	at	280	nm	and	
expressed	as	mg/100	g	dry	matter.	
2.2.3.	Determination	of	antidiabetic	activity	of	methanolic	A.	
wilkesiana	leaves	extracts	
	
2.2.3.1.	Experimental	animals	
	
Male	Sprague‐Dawley	albino	rats,	weighing	180‐200	g	were	
obtained	 from	 the	 animal	 house	 of	 Faculty	 of	 Pharmacy,	
Mansoura	University,	Egypt.	The	rats	were	kept	for	adaptation	
under	 normal	 laboratory	 conditions	 for	 7	 days	 before	 the	
beginning	of	the	experiment.	All	rats	were	fed	on	a	normal	diet	
and	allowed	free	access	to	water.	After	acclimatization,	the	rats	
were	housed	in	metabolic	cages	and	divided	randomly	into	six	
groups	 having	 six	 animals	 in	 each	 group.	 Animal	
experimentation	described	in	the	study	was	strictly	conducted	
in	accordance	with	the	guidelines	prescribed	by	the	University	
Ethical	Committee.		
Group	 1,	 represents	 normal	 rats	 by	 means	 non	 diabetic,	
which	were	 fed	with	normal	diet	 and	 received	saline	 solution	
for	30	days.	The	remaining	rats	were	fasted	for	24	hours,	then	
intraperitoneally	injected	with	streptozotocin	freshly	prepared	
in	0.10	M	citrate	buffer,	pH	=	4.5	at	a	dose	of	4.5	mg/100	g	body	
weight	 (b.	 wt.)	 to	 induce	 diabetes	 mellitus,	 according	 to	
Ghasemi	 et	 al.,	 [16].	 In	 order	 to	 stave	 off	 the	 hypoglycaemia	
during	 the	 first	day	after	 the	streptozotocin	 injection,	diabetic	
rats	 were	 given	 5%	 glucose	 solution	 orally	 as	 reported	 by	
Orhan	et	al.,	[17].	Blood	glucose	level	of	rats	was	determined	72	
hours	 post‐injection;	 rats	 were	 fasted	 for	 18	 hours	 before	
determination.	Rats	with	blood	glucose	levels	over	300	mg/dL	
were	considered	sufficiently	as	streptozotocin‐diabetic	rats	and	
ready	 for	 treating	 with	 the	 extract.	 Then,	 diabetic	 rats	 were	
randomly	 divided	 into	 5	 groups	 (6	 rats	 for	 each).	 Group	 2,	
represents	diabetic	control	rats,	 received	a	normal	diet	 for	30	
days	without	any	 treatment.	Group	3,	 represents	diabetic	 rats	
treated	with	metformin	 hydrochloride	 powder	 as	 a	 reference	
drug	in	dose	50	mg/100g	b.	wt.	Groups	4,	5	and	6	were	diabetic	
rats	 administered	with	 crude	methanolic	Acalypha	wilkesiana	
leaves	 extract	 in	 doses	 of	 10,	 20	 and	 40	 mg/100g	 b.	 wt.,	
respectively.	 Reference	 drug	 and	 crude	 methanolic	 extract	
were	dissolved	 in	saline	solution	(Sodium	chloride,	0.9%)	and	
given	orally	by	a	 stomach	 tube	after	 fasting	 for	2	hours,	daily	
for	30	days.	
Blood	 samples	 were	 collected	 from	 the	 eye	 canthus	 by	
heparinized	 tubes	 every	 10	 days	 after	 the	 beginning	 of	 the	
experiment.	 Then,	 each	 blood	 sample	 was	 divided	 into	 two	
portions.	 Centrifugation	 was	 carried	 out	 to	 a	 first	 portion	 to	
obtain	 clear	 serum	and	 the	 fasting	 serum	glucose	 levels	were	
determined	 immediately.	 Serum	 blood	 samples	 were	 kept	 at	
refrigerator	under	freezing	conditions	for	the	determination	of	
the	 other	parameters	 included	 liver	 functions	 (ALT	 and	AST),	
kidney	 functions	 (creatinine	 and	 urea)	 and	 lipid	 profile	
(Triglycerides,	 total	 cholesterol,	 HDL‐C,	 LDL‐C	 and	 VLDL‐C).	
The	second	portion	was	treated	with	10%	of	ethylene	diamine	
tetracetic	 acid	 (EDTA)	 with	 a	 good	 shaking	 to	 determine	 the	
complete	blood	count	(CBC)	as	a	haematological	analysis.	
	
2.2.3.2.	Chemical	analysis	of	blood	
	
Serum	glucose	was	determined	by	a	colorimetric	enzymatic	
method	glucose	oxidase	(GOD)	described	in	commercial	kits	by	
Spinreact	 (Spain)	 according	 to	 Trinder	 [18].	 Liver	 functions	
(ALT	 and	 AST)	 were	 determined	 as	 described	 in	 commercial	
kits	 by	Randox	 (United	Kingdom)	 according	 to	 the	method	 of	
Reitman	and	Frankel	[19].	Kidney	functions	(Serum	creatinine	
and	urea)	were	determined	by	a	colorimetric	method	according	
to	 Larsen	 [20];	 Fawcett	 and	 Scott	 [21],	 respectively,	 as	
described	 in	 commercial	 kits	 by	Human	 (Germany).	 The	 lipid	
profile,	 triglycerides	 (TG),	 total	 cholesterol	 (TC)	 and	 high	
density	 lipoprotein	 cholesterol	 (HDL‐C)	 were	 determined	 by	
enzymatic	 colorimetric	 method	 of	 [22‐24]	 described	 in	 a	
commercial	kits	by	Human	(Germany).	
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Table	1.	HPLC	analysis	of	polyphenols	of	methanolic	Acalypha	wilkesiana	leaves	extract.	
Compound	 Concentration	(mg/100	g)	 Compound	 Concentration	(mg/100	g)	
Apigenin	 624.15	 Caffeic	acid 94.03
Caffeine	 33.78	 Catechin 890.66
Catechol	 32.21	 Chlorogenic	acid	 62.61	
Chrysin	 ‐	 Cinnamic	acid	 ‐	
Coumarin	 29.16	 Ellagic	acid	 522.36	
Ferulic	acid	 139.27	 Gallic	acid	 11.70	
Hisperidin	 ‐	 Kampferol 227.16
Luteolin	 137.52	 Naringenin 10.55
p‐Coumaric	acid	 42.76	 p‐OH‐Benzoic	acid 31.24
Protocatechouic	 44.18	 Pyrogallol 128.16
Quercetin	 311.25	 Rosmarinic	acid 9.15
Rutin	 95.74	 Salicylic	acid ‐
Syringic	acid	 32.62	 Vanillic	acid ‐
	
	
Serum	 low	 density	 lipoprotein	 cholesterol	 (LDL‐C)	 and	
very	 low	 density	 lipoprotein	 cholesterol	 (VLDL‐C)	
concentrations	 were	 calculated	 using	 the	 Friedewald	 [25]	
equations	as	follows:	
	
VLDL–C	=	TG/5		 	 	 	 	 (1)	
	
LDL–C	=	TC	–	(HDL–C	+	VLDL–C)		 	 	 (2)	
	
The	 atherogenic	 indices	 were	 calculated	 as	 reported	 by	
Ikewuchi	and	Ikewuchi	[26]	using	the	following	equations:	
	
Cardiac	risk	ratio	=
TC
HDLc
		 	 	 	 (3)		
		
Atherogeniс	coefficient	=	
 TC‐ HDLc
HDLc
 
 
  
		 	 (4)	
	
Atherogenic	index	of	plasma=	log	
TG
HDLc
		 	 (5)		
	
2.2.3.3.	Haematological	analysis	
	
All	 haematological	 tests	 were	 made	 using	 apparatus	
namely	 ABX	 Micros	 60	 which	 a	 fully	 automated	 hematology	
analyzer	from	Sysmex	Corporation	international	company	[27].	
Micros	60	 is	an	 ideal	choice	 for	 the	determination	of	up	 to	18	
fully	 automated	 parameters	 including	 hemoglobin	 (Hb),	 red	
blood	 cells	 count	 (RBC),	 hematocrit	 (Hct),	 packed	 cell	 volume	
(PCV),	 mean	 corpuscular	 volume	 (MCV),	 mean	 corpuscular	
hemoglobin	 (MCH),	 mean	 corpuscular	 hemoglobin	 concent‐
ration	 (MCHC),	 red	 cell	 distribution	 width	 (RDW),	 platelets	
count	 (Plt),	 platelets	 hematocrit	 (PCT),	 mean	 platelet	 volume	
(MPV),	 platelet	 distribution	 width	 (PDW),	 white	 blood	 cells	
count	 (WBC)	 and	 WBC	 differential:	 Lymphocytes	 (LYM),	
Monocytes	 (MON)	and	Granulocytes	 (GRA).	 It	 can	perform	60	
samples	 per	 hour	 in	 open	 or	 closed	 tube	 forms	 for	 sample	
volume	of	10	µL	of	whole	blood	per	cycle.	
	
2.2.4.	Statistical	analysis	
	
Statistical	 analyses	 for	obtained	data	were	done	using	 the	
SPSS	 statistical	 software	 package.	 All	 comparisons	 were	 first	
subjected	to	one	way	analysis	of	variance	(ANOVA)	and	signifi‐
cant	 differences	 between	 treatment	 means	 were	 determined	
using	Duncan’s	multiple	rang	test	at	p	<	0.05	as	the	level	of	the	
significance.		
	
3.	Results	and	discussion		
	
3.1.	Analysis	of	polyphenols	by	HPLC	
	
High	 performance	 liquid	 chromatography	 procedure	 was	
used	 for	 qualitative	 and	 quantitative	 analysis	 of	 polyphenolic	
compounds	 in	methanolic	 Acalypha	wilkesiana	 leaves	 extract.	
Twenty	 six	 polyphenolic	 compounds	 were	 available	 as	
authentic	samples	namely:	apigenin,	caffeine,	catechol,	chrysin,	
coumarin,	 ferulic	 acid,	 hisperidin,	 luteolin,	 p‐coumaric	 acid,	
protocatechouic,	 quercetin,	 rutin,	 syringic	 acid,	 caffeic	 acid,	
catechin,	 chlorogenic	 acid,	 cinnamic	 acid,	 ellagic	 acid,	 gallic	
acid,	 kampferol,	 naringenin,	 p‐OH‐benzoic	 acid,	 pyrogallol,	
rosmarinic	 acid,	 salicylic	 acid	 and	 vanillic	 acid	 were	 used	 to	
identify	the	corresponding	components	in	Acalypha	wilkesiana	
leaves	extract	polyphenols.	
Data	 in	 Table	 1	 reveal	 that	 twenty	 one	 compounds	 with	
different	 retention	 times	 were	 recognized	 in	 HPLC	
chromatogram.	 From	 the	 same	 table,	 it	 could	 be	 noticed	 that	
catechin,	 apigenin,	 ellagic	 acid,	 quercetin	 and	 kampferol	were	
the	predominant	indentified	component	in	Acalypha	wilkesiana	
leaves	extract	as	percentages	of	29.91,	20.96,	17.54,	10.45	and	
7.63%,	respectively.	Followed	by	 ferulic	acid	(4.67%),	 luteolin	
(4.61%),	 pyrogallol	 (4.30%),	 rutin	 (3.21%),	 caffeic	 acid	
(3.15%),	 chlorogenic	 acid	 (2.10%),	 protocatechouic	 acid	
(1.48%),	 p‐coumaric	 acid	 (1.43%),	 caffiene	 (1.13%),	 syrigic	
acid	(1.09%),	catechol	(1.08%)	and	p‐OH‐benzoic	acid	(1.05%),	
in	 addition	 to	 traces	 of	 coumarin,	 gallic	 acid,	 naringenin	 and	
rosemarinic	acid.	While,	five	polyphenolic	compounds,	namely:	
chrysin,	 hisperidin,	 cinnamic	 acid,	 salicylic	 acid	 and	 vanillic	
acid	were	absence	in	the	methanolic	leaves	extract	of	Acalypha	
wilkesiana.	
Ours	results	were	agreed	with	those	obtained	by	Ikewuchi	
et	 al.,	 [28]	 who	 detected	 twenty	 nine	 known	 flavonoids	 in	
aqueous	Acalypha	wilkesiana	 leaves	 extract,	 consisting	mainly	
of	 apigenin,	 quercetin,	 naringenin,	 kaempferol,	 epicatechin,	
catechin,	 ellagic	 acid,	 butein,	 myricetin,	 biochanin,	 baicalein,	
gallocatechin,	 robinetin,	 silymarin,	 and	epigallocatechin	29.77,	
14.97,	11.12,	10.62,	9.05,	4.37,	2.36,	2.34,	2.25,	2.08,	1.76,	1.72,	
1.14,	 1.13	 and	 1.11%,	 respectively.	 However,	 the	 preliminary	
phytochemical	screening	of	the	methanolic	A.	wilkesiana	leaves	
extract	 revealed	 the	 presence	 of	 alkaloids,	 flavonoids	
(catechins	and	flavones),	saponins	and	tannins	(Table	1),	all	of	
which	 have	 potential	 health	 promoting	 effects,	 at	 least	 under	
some	circumstances	[29].	
	
3.2.	Effect	of	crude	methanolic	of	Acalypha	wilkesiana	leaves	
extracts	on	blood	glucose	level	
	
The	obtained	data	 in	Table	2	 indicate	 that	 the	 injection	of	
streptozotocin	at	the	dose	4.5	mg/100	g	body	weight	caused	a	
highly	 significant	 (p	 <	 0.05)	 increase	 in	 blood	 glucose	 level	
from	 102	 to	 387	mg/dL	 for	 non‐diabetic	 and	 diabetic	 rats	 at	
zero	 time,	 respectively.	 In	 addition,	 gradual	 increasing	 was	
observed	during	the	experimental	periods	(10,	20	and	30	days)	
until	 reaching	 the	 maximum	 level	 of	 464	mg/dL	 for	 diabetic	
rats	at	the	end	of	the	experiment.	This	increase	may	be	due	to	
the	 destructive	 effect	 of	 streptozotocin	 on	 β‐cells	 of	 islets	 of	
Langerhans	which	lead	to	insulin	deficiency.		
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Table	2.	Effect	of	crude	methanolic	leaves	extract	of	Acalypha	wilkesiana	on	levels	of	blood	glucose	(mg/dL)	in	diabetic	rats.	
Treatment	
period	
Normal		
control		
Diabetic		
Control	
Diabetic	+		
metformin	
Diabetic	+	A.	wilkesiana	extract	at	a	dose	
10	mg/100 g	b.	wt. 20	mg/100	g	b.	wt.	 40	mg/100 g	b.	wt.
Zero	time	 102±3.75	 387±14.08	a	 300±12.96	a,b 390±6.42	a 388±15.22	a	 378±11.03	a
10	days	 104±3.87	 400±11.42	a	 230±6.92	a,b	 355±13.46	a,b,с	 300±9.42	a,b,с	 281±13.76	a,b,с	
20	days	 99±2.65	 428±16.42	a	 151±4.42	a,b 298±15.99	a,b,с 229±6.42	a,b,с	 169±6.42	a,b,с
30	days	 103±2.05	 464±20.20	a	 109±3.15	b	 183±4.13	a,b,с	 120±7.01	a,b,с	 105±4.66	b	
a	The	values	are	mean±SD	of	6	rats	in	each	group,	significantly	different	from	normal	control	at	p	<	0.05.	
b	The	values	are	mean±SD	of	6	rats	in	each	group,	significantly	different	from	diabetic	control	at	p	<	0.05.	
c	The	values	are	mean±SD	of	6	rats	in	each	group,	significantly	different	from	diabetic	+	metformin	at	p	<	0.05.	
	
	
Table	3.	Effect	of	crude	methanolic	Acalypha	wilkesiana	leaves	extract	on	liver	functions	(IU/L)	activities	in	diabetic	rats	*.	
Liver	functions	
(IU/L)	
Treatment	
period	
Normal		
control		
Diabetic	
control		
Diabetic	+	
metformin	
Diabetic	+	A.	wilkesiana	extract	at	a	dose	
10	mg/100 g	b.	wt 20	mg/100	g	b.	wt	 40	mg/100 g	b.	wt
ALT	 Zero	time	 26±2.96	 49±4.44	a 51±3.26	a,b 47±4.71	a,b,с 49±3.22	a,b,с	 48±3.84	a,b,с
30	days	 27±1.16	 71±5.09	a 34±4.11	a,b 33±4.25	a,b 27±2.57	b,с	 26±3.02	b,с
AST	 Zero	time	 34±2.11	 54±6.06	a 61±5.72	a,b 64±5.12	a,b 57±4.65	a,b	 53±5.04	a
30	days	 40±4.13	 84±8.14	a	 47±3.55	a,b	 53±4.41	a,b,с	 41±4.89	b,с	 31±1.37	a,b,с	
*	The	values	are	mean±SD	of	6	rats	in	each	group.		
a	Significantly	different	from	normal	control	at	p	<	0.05.	
b	Significantly	different	from	diabetic	control	at	p	<	0.05.	
c	Significantly	different	from	diabetic+metformin	at	p	<	0.05.	
	
	
Moreover,	 the	 absence	 of	 available	 insulin	 in	 blood	
circulation,	 these	 may	 be	 the	 main	 causes	 of	 hyperglycemia,	
which	 observed	 in	 the	 treated	 rats	 with	 streptozotocin	 as	
achieved	 by	 Vessal	 et	al.,	 [4].	 Also,	 Lenzen	 [30]	 reported	 that	
the	 significant	 increase	 in	 the	 levels	 of	 blood	 glucose	 in	 STZ‐
induced	diabetic	rats	could	be	due	 to	a	beta	cytotoxic	 induces	
chemical	diabetes	through	damaging	insulin‐secreting	cells.	
It	could	be	reported	that	the	most	effective	dose	of	reducing	
blood	 glucose	 level	 was	 demonstrated	 at	 40	mg/100	 g	 b.	wt.	
which	 decreased	 this	 parameter	 to	 105	mg/dL	 after	 30	 days,	
where	the	maximum	reduction	of	about	77.50%	was	obtained	
compared	with	 diabetic	 control	 rats.	While,	 treated	 rats	 with	
metformin	HCl	achieved	a	76.50%,	reducing	blood	glucose	level	
at	 the	 dose	 50	 mg/100	 g	 b.	 wt.	 after	 30	 days.	 The	 initial	
antihyperglycemic	 activity	 was	 observed	 after	 ten	 days,	 then	
the	 blood	 glucose	 level	 gradually	 decreased	 for	 all	 groups	
during	the	experimental	periods.	The	methanolic	A.	wilkesiana	
leaves	extract	at	doses	10,	20	and	40	mg/100g	b.	wt.	 reduced	
blood	 glucose	 levels	 by	 11,	 25	 and	 30%,	 respectively,	
comparing	with	that	observed	in	diabetic	control	rats	after	10	
days	 (Table	 2).	 Our	 data	 were	 in	 accordance	 with	 those	
obtained	 by	 Ikewuchi	 et	 al.,	 [28]	 who	 used	 10,	 20	 and	 30	
mg/100g	b.	wt.	of	aqueous	A.	wilkesiana	 leaves	extract,	which	
decreased	 blood	 glucose	 levels	 by	 8.20,	 20.86	 and	 21.34%,	
respectively,	 compared	 with	 untreated	 diabetic	 rats	 after	 10	
days.	Additionally,	our	results	run	parallel	with	those	obtained	
by	Al‐Attar	[31]	who	illustrated	11.6%	as	a	reduced	percentage	
of	 blood	 glucose	 level	 by	 using	 aqueous	 A.	wilkesiana	 leaves	
extract	in	diabetic	mice	after	30	days.	Furthermore,	Odoh	et	al.,	
[32]	showed	that	the	most	significant	reduction	of	fasting	blood	
glucose	 level	 (48.36%)	was	 observed	 for	 200	mg/kg	 b.	wt.	 of	
methanolic	 A.	 wilkesiana	 root	 extract	 in	 alloxan‐induced	
diabetic	 rats.	Moreover,	 these	 previous	 comparisons	 demons‐
trated	 that	 hypoglycemic	 activity	 of	 the	 methanolic	 A.	
wilkesiana	 leaves	extract	was	more	effective	 than	the	aqueous	
ones	 at	 the	 same	 experimental	 period.	 Also,	 the	 higher	
percentage	reduction	 in	blood	glucose	 levels,	produced	by	the	
extract	in	this	study,	supports	the	use	of	A.	wilkesiana	leaves	in	
the	management	of	diabetes	mellitus.	
Several	 studies	 reported	 that	 the	 A.	 wilkesiana	 leaves	
contain	 polyphenols	 as	 bioactive	 compounds	 such	 as	
querecetin	 which	 produces	 an	 increase	 in	 the	 number	 of	
pancreatic	 islet	cells,	probably	 increase	 insulin	release	 in	STZ‐
diabetic	 rats	 and	 induces	 the	 hepatic	 glucokinase	 enzyme.	
Thus,	 the	 lowering	 property	 of	 plasma	 glucose	 could	 also	 be	
attributed	to	the	ability	of	querecetin	to	regenerate	pancreatic	
β‐cells	 and	 to	 increase	 insulin	 release	 [4].	 Finally,	 it	 could	 be	
concluded	 that	 lowering	 blood	 glucose	 levels,	 which	 was	
observed	in	the	diabetic	animals	may	be	due	to	the	stimulation	
of	β‐cells	of	pancreatic	islets	and	mediated	through	stimulation	
of	 insulin	 release	 resembling	 the	 oral	 hypoglycemic	 drugs	 or	
peripheral	glucose	utilization	[33].	
		
3.3.	Effect	of	crude	methanolic	extracts	of	Acalypha	
wilkesiana	leaves	on	liver	functions	
	
Alanine	 amino	 transferase	 (ALT)	 and	 aspartate	 amino	
transferase	 (AST)	 activities	 are	 known	 as	 cytosolic	 marker	
enzymes	reflecting	hepatocellular	necrosis	as	they	are	released	
into	the	blood	after	damaging	of	the	cell	membrane;	 therefore	
both	enzymes	are	used	as	 indicators	 for	hepatic	damage	 [34].	
Liver	 functions	 during	 this	 investigation	 were	 examined	
through	the	determination	of	ALT	and	AST	activities	 in	serum	
of	 non‐diabetic	 and	 STZ‐diabetic	 rats.	 It	 is	 clear	 that	ALT	 and	
AST	increased	significantly	from	26	and	34	IU/L	in	non‐diabetic	
rats	 to	 49	 and	 63	 IU/L,	 respectively	 in	 diabetic	 control	 rats	
(Table	3).	Such	a	significant	increase	of	ALT	and	AST	activities	
as	 shown	 suggest	 the	 possible	 necrotic	 injury	 of	 the	 liver	 or	
cholestasis	with	hepatocellular	necrosis	[35].	
Data	 in	Table	3	clearly	 indicate	no	significance	differences	
between	 normal	 and	 treated	 rats	 with	 the	 methanolic	 leaves	
extract	of	A.	wilkesiana	at	both	doses	20	and	40	mg/100	g	b.	wt.	
for	ALT	activity	values	at	the	end	of	the	experimental	period.	In	
addition,	 AST	 activity	 value	 differences	 were	 not	 significant	
between	 normal	 control	 and	 treated	 rats	 with	 A.	 wilkesiana	
leaves	 extract	 at	 dose	20	mg/100g	b.	wt.	 after	 30	days.	 From	
the	 same	 table,	 it	 could	 be	 observed	 that	 treatment	 with	
methanolic	A.	wilkesiana	 leaves	 extract	 in	 all	 doses	was	more	
effective	 for	 gradually	 reducing	 of	 ALT	 and	 AST	 levels	 than	
treated	diabetic	rats	with	metformin	HCl.	
Our	 results	 for	ALT	 levels	were	more	effectual	 than	 those	
obtained	 by	 Ikewuchi	 et	 al.,	 [28]	 who	 found	 no	 significant	
differences	 between	 untreated	 diabetic	 and	 diabetic	 rats	
treated	with	aqueous	A.	wilkesiana	leaves	extract.	Furthermore,	
methanolic	A.	wilkesiana	 leaves	extract	 reduced	AST	values	 to	
about	63%	compared	with	 Ikewuchi	et	al.,	 [28]	who	offered	a	
lower	reduction	value	of	33%	using	an	aqueous	extract	at	 the	
end	of	the	experimental	period.	The	restoration	of	AST	and	ALT	
activities	 to	 their	 respective	 normal	 levels	 after	 supplemen‐
tation	 of	 methanolic	 leaves	 extract	 of	 A.	 wilkesiana	 further	
strengthens	 the	 antidiabetogenic	 effect	 of	 this	 extract.	
Moreover,	it	has	been	concluded	that	the	decrease	in	the	serum	
transaminase	 enzymes	 in	 STZ‐induced	 diabetic	 rats	 by	 A.	
wilkesiana	 leaves	extract	may	be	due	 to	 the	prevention	of	 the	
leakage	 of	 intracellular	 enzymes	 by	 its	 membrane	 stabilizing	
activity.	
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Table	4.	Effect	of	crude	methanolic	Acalypha	wilkesiana	leaves	extract	on	kidney	functions	(mg/dL)	levels	in	diabetic	rats	*.	
Kidney	functions	
(mg/dL)	
Treatment		
period	
Normal		
control		
Diabetic		
control		
Diabetic	+	
metformin	
Diabetic	+	A.	wilkesiana	extract	at	a	dose	
10	mg/100	g	b.	wt	 20	mg/100	g	b.	wt	 40	mg/100	g	b.	wt	
Creatinine	 Zero	time	 1.3±0.05	 1.6±0.03	 1.9±0.02	 1.5±0.07	 1.4±0.05	 1.6±0.02	
30	days	 1.2±0.01	 2.3±0.08 1.4±0.01 1.1±0.02 1.2±0.03	 1.0±0.02
Urea	 Zero	time	 51±2.03	 77±2.31	a 72±1.56	a,b 70±1.15	a,b 70±1.77	a,b	 71±2.72	a,b
30	days	 55±1.45	 99±3.11	a 69±2.08	a,b 73±3.20	a,b 61±1.66	a,b,c	 52±1.48	b,c
*	The	values	are	mean±SD	of	6	rats	in	each	group.		
a	Significantly	different	from	normal	control	at	p	<	0.05.	
b	Significantly	different	from	diabetic	control	at	p	<	0.05.	
c	Significantly	different	from	diabetic+metformin	at	p	<	0.05.	
	
	
Table	5.	Effect	of	crude	methanolic	leaves	extract	of	Acalypha	wilkesiana	on	lipid	profile	(mg/dL)	levels	in	diabetic	rats	*.	
Lipid	profile	
(mg/dL)	
Treatment	
period	
Normal		
control		
Diabetic	
control		
Diabetic	+	
metformin	
Diabetic	+	A.	wilkesiana	extract	at	a	dose	
10	mg/100	g	b.	wt 20	mg/100	g	b.	wt	 40	mg/100	g	b.	wt
Triglycerides	 Zero	time	 171±3.67	 289±11.45	a 280±8.20	a,b 276±7.33	a,b 280±6.38	a,b	 28±8.33	a,b
30	days	 168±5.15	 301±9.78	a	 188±9.64	a,b	 205±6.21	a,b,c	 183±4.05	a,b,c	 171±6.96	b,c	
Total	cholesterol	 Zero	time	 195±4.04	 380±9.85	a	 377±9.72	a	 383±7.13	a,c	 375±5.74	a,b,c	 386±8.88	a,b,c	
30	days	 199±6.51	 408±12.55	a	 200±7.51a,b	 301±5.45	a,b,c,f	 210±4.42	a,b,c	 190±3.91	a,b,c	
HDL–C	 Zero	time	 47±1.76	 26±2.16	a 28±3.11	a,b 29±2.60	a,b 30±2.88	a,b	 29±4.01	a,b
30	days	 39±1.45	 23±4.33	a 40±3.96	b 32±3.84	a,b,c 48±4.36	a,b,c	 43±4.55	a,c
LDL–C	 Zero	time	 114±2.60	 296±3.10	a 293±2.67	a 299±3.04	a,c 289±3.44	a,b,c	 301±4.20	a,b,c
30	days	 126±1.36	 325±5.26	a 122±2.96	b 228±5.11	a,b,c 125±2.85	b,c	 113±3.71	a,b,c
VLDL–C	 Zero	time	 34±0.66	 58±1.11	a 56±0.85	a 55±1.12	a 56±0.55	a	 56±1.97	a
30	days	 34±0.35	 60±0.99	a	 38±0.77	a,b	 41±1.08	a,b	 37±0.64	b	 34±1.04	b,c	
*	The	values	are	mean±SD	of	6	rats	in	each	group.		
a	Significantly	different	from	normal	control	at	p	<	0.05.	
b	Significantly	different	from	diabetic	control	at	p	<	0.05.	
c	Significantly	different	from	diabetic+metformin	at	p	<	0.05.	
	
	
3.4.	Effect	of	crude	methanolic	Acalypha	wilkesiana	leaves	
extracts	on	kidney	functions	
	
Determination	of	 serum	creatinine	and	urea	were	used	as	
indicators	 for	 kidney	 functions.	 The	 effect	 of	 methanolic	 A.	
wilkesiana	leaves	extract	on	serum	creatinine	and	urea	levels	in	
STZ‐diabetic	 rats	 is	 illustrated	 in	 Table	 4.	 It	 could	 be	 noticed	
that	 injection	with	 streptozocin	 induced	 a	 significant	 increase	
in	serum	creatinine	and	urea	levels	from	1.3	and	51.0	to	1.6	and	
77.0	 mg/dL	 respectively,	 compared	 with	 non‐diabetic	 rats	 at	
the	 beginning	 of	 the	 experiment.	 These	 elevations	 may	 be	
attributed	to	the	diverse	hormonal	and	metabolic	changes	that	
accompany	 diabetes	 and	 the	 toxic	 effect	 of	 streptozocin	 on	
kidney	 [36].	 It	 could	 be	 perceived	 from	 Table	 4	 that	 no	
significance	differences	between	normal	and	 treated	rats	with	
the	methanolic	extract	at	doses	10,	20	and	40	mg/100	g	b.	wt.	
for	creatinine	 levels	at	 the	end	of	 the	experimental	period.	On	
the	 other	 hand,	 serum	 urea	 values	 were	 decreased	 with	
increasing	 the	 concentration	 of	 methanolic	 extract	 and	 the	
period	 of	 experiment	 to	 reach	 52	mg/dL	 as	 a	 non	 significant	
value	at	the	dose	40	mg/100	b.	wt.	compared	with	normal	rats	
at	the	end	of	the	experimental	period.	
Data	 in	Table	4	 show	 that	methanolic	A.	wilkesiana	 leaves	
extract	at	doses	10,	20	and	40	mg/100	g	b.	wt.	reduced	serum	
urea	levels	to	26.3,	38.4	and	47.5%,	respectively,	after	30	days	
of	 the	 experiment	 comparing	 with	 diabetic	 control	 rats.	
Previous	results	run	parallel	with	those	of	Ikewuchi	et	al.,	[28]	
who	 established	 that	 the	 reduction	 of	 blood	 urea	 represents	
33.4,	 47.8	 and	 56.5%	 at	 doses	 10,	 20	 and	 30	mg/100g	 b.	wt.	
respectively	of	aqueous	A.	wilkesiana	 leaves	extract	at	the	end	
of	 the	 experimental	 period.	 The	 improvement	 of	 the	 kidney	
functions	 associated	 with	 treating	 the	 diabetic	 rats	 with	 the	
methanolic	leaves	extract	of	A.	wilkesiana	could	be	attributed	to	
its	 antidiabetic	 action	 resulting	 in	 alleviation	 of	 altered	
metabolic	 status	 in	 animals	 and	 to	 its	 potent	 antioxidant	
potential	which	 have	 scavenge	 free	 radicals	 and	 thereby	may	
protect	renal	cells	from	oxidative	stress.	
	
3.5.	Effect	of	crude	methanolic	Acalypha	wilkesiana	leaves	
extracts	on	lipid	profile	
	
Recorded	 data	 in	 Table	 5	 reveal	 that	 serum	 triglyceride,	
total	cholesterol,	LDL‐C	and	VLDL‐C	values	increased	from	171,	
195,	114	and	34	 in	non‐diabetic	 rats	 to	289,	380,	296	and	58	
mg/dL,	 respectively	 in	 diabetic	 rats	 by	 injection	 with	
streptozocin.	On	the	other	hand,	Table	5	declares	that	there	is	a	
highly	 significant	 decrease	 in	 serum	 HDL‐C	 level	 since	 it	
reached	 26	 mg/dL	 for	 STZ‐diabetic	 rats,	 comparing	 with	 47	
mg/dL	 for	 normal	 rats	 at	 the	 beginning	 of	 the	 experiment.	
Many	 compositional	 abnormalities	 in	 the	 lipoproteins	 have	
been	 found	 in	 diabetic	 patients	 and	 the	 major	 cause	 of	
hypertriglyceridemia	 appeared	 to	 be	 the	 overproduction	 of	
VLDL,	which	 is	 attributed	 to	 hyperglycemia	 and/or	 increased	
influx	of	free	fatty	acids	in	the	liver	[37].	Also,	Fernandez	et	al.,	
[38]	suggested	that	increasing	in	LDL	cholesterol	level	(the	risk	
factor	 for	 cardiovascular	 disease)	 may	 be	 attributed	 to	 some	
reasons	 such	 as	 an	 increase	 of	 intestinal	 absorption	 of	 lipid,	
cholesterol	 synthesis	 and	 liver	 lipid	 synthesis	 or	 liver	
dysfunction.	 In	 addition,	 the	decrease	 in	 the	 serum	HDL	 level	
may	 be	 due	 to	 the	 decrease	 of	 lecithin	 cholesterol	 acetyl	
transferase	which	responsible	for	estrification	of	cholesterol	in	
HDL.	
It	could	be	noticed,	from	Table	5	that	triglyceride	decreased	
with	increasing	the	extract	concentration	and	the	experimental	
period.	 Accordingly,	 the	 treatment	 of	 diabetic	 rats	 with	 40	
mg/100	g	b.	wt.	of	methanolic	A.	wilkesiana	leaves	extract	was	
the	 most	 effective	 concentration,	 where	 the	 reduction	
percentage	of	triglyceride	level	achieves	about	43%	at	the	end	
of	 the	 experiment	 compared	with	 diabetic	 control	 rats.	 These	
findings	were	in	the	same	line	of	those	reported	by	Ikewuchi	et	
al.,	 [28]	who	 conducted	 that	 triglycerides	value	were	 reduced	
in	percentages	of	10,	14	and	24%	by	using	the	doses	10,	20	and	
30	mg/100g	b.	wt.	respectively,	of	aqueous	A.	wilkesiana	leaves	
extract.	Data	presented	in	Table	5	show	that	the	administration	
of	 diabetic	 rats	 with	 40	 mg/100g	 b.	 wt.	 of	 methanolic	 A.	
wilkesiana	leaves	extract	for	30	days	led	to	the	highest	reducing	
effect	of	total	cholesterol	level,	which	reached	190	mg/dL	with	
a	 reduced	 percentage	 of	 53%	 comparing	 with	 untreated	
diabetic	 rats.	 On	 the	 contrary,	 It	 has	 been	 reported	 that	
aqueous	 A.	 wilkesiana	 leaves	 extract	 have	 a	 low	 effect	 in	
reducing	 total	cholesterol	 levels,	which	accomplished	4,	4	and	
19%	 by	 using	 the	 doses	 10,	 20	 and	 30	 mg/100	 g	 b.	 wt.,	
respectively	[28].		
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Table	6.	Effect	of	crude	methanolic	leaves	extract	of	Acalypha	wilkesiana	on	atherogenic	indices	in	diabetic	rats	*.	
Atherogenic	
indices	
Treatment	
period	
Normal		
control		
Diabetic	
control		
Diabetic	+	
metformin	
Diabetic	+	A.	wilkesiana	extract	at	a	dose	
10	mg/100	g	b.	wt 20	mg/100	g	b.	wt	 40	mg/100	g	b.	wt
Cardiac	risk	
ratio	
Zero	time	 4.15±0.27	 14.62±0.66	a	 13.46±0.54	a	 13.21±0.38	a	 12.50±0.75	a	 13.31±0.35	a	
30	days	 5.10±0.17	 17.74±0.43	a 5.00±0.14	a,b 9.41±0.27	a,b,c 4.38±0.11	b	 4.42±0.13	b
Atherogenic	
coefficient	
Zero	time	 3.15±0.11	 13.62±0.46	a 12.46±0.32	a 12.21±0.41	a 11.50±0.29	a	 12.31±0.36	a
30	days	 4.10±0.27	 16.74±0.58	a	 4.00±0.27	a,b	 8.41±0.27	a,b,c	 3.38±0.27	b,c	 3.42±0.27	b,c	
Atherogenic	
index	of	
plasma	
Zero	time	 0.56±0.04	 1.05±0.11 1.00±0.07 0.98±0.06 0.97±0.08 0.99±0.07
30	days	 0.63±0.03	 1.12±0.12	 0.67±0.04	 0.81±0.05	 0.58±0.02	 0.60±0.02	
*	The	values	are	mean±SD	of	6	rats	in	each	group.	
a	Significantly	different	from	normal	control	at	p	<	0.05.	
b	Significantly	different	from	diabetic	control	at	p	<	0.05.	
c	Significantly	different	from	diabetic+metformin	at	p	<	0.05.	
	
	
Table	7.	Effect	of	treatment	of	crude	methanol	leaves	extract	of	Acalypha	wilkesiana	on	levels	of	Hb	(g/dL)	in	diabetic	rats	*.		
Treatment	period	 Normal		
control		
Diabetic	
control		
Diabetic	+
metformin	
Diabetic	+	A.	wilkesiana	extract	at	a	dose	
10	mg/100	g	b.	wt	 20	mg/100	g	b.	wt.	 40	mg/100	g	b.	wt	
Zero	time	 14.2±0.54	 11.1±0.34	 10.9±0.29	 11.4±0.32	 11.0.±0.42	 11.0±0.54	
10	days	 14.8±0.43	 10.6±0.44 11.1±0.31 11.9±0.43 12.3±0.35 13.6±0.44
20	days	 13.9±0.65	 10.9±0.34	 11.7±0.42	 12.8±0.54	 13.0±0.45	 14.6±0.54	
30	days	 15.0±0.64	 10.3±0.31 12.5±0.53 13.1±0.63 13.6±0.48 15.0±0.62
*	The	values	are	mean±SD	of	6	rats	in	each	group.		
	
	
At	the	same	time,	a	87%,	raising	in	the	percentage	of	serum	
HDL‐C	 has	 been	 achieved	 when	 diabetic	 rats	 administrated	
with	 the	 dose	 40	mg/100	 g	 b.	wt.,	while	 treated	 diabetic	 rats	
with	 aqueous	 A.	 wilkesiana	 leaves	 extract	 have	 a	 moderate	
effect	in	increasing	HDL‐C	value	which	reached	55,	46	and	66%	
by	using	the	doses	10,	20	and	30	mg/100	g	b.	wt.,	respectively	
[28].	From	the	same	table,	it	could	be	revealed	that	all	doses	of	
methanolic	 A.	wilkesiana	 leaves	 extract	 caused	 a	 decrease	 in	
serum	LDL‐C	and	VLDL‐C	which	became	65	and	43%	after	30	
days	 at	 a	 dose	 of	 40	mg/100	 g	 b.	wt.	 respectively,	 compared	
with	 diabetic	 control	 rats,	 indicating	 the	 likely	 cardio‐
protective	 effect	 of	 the	 extract	 at	 this	 dose.	 These	 decreased	
values	of	both	LDL‐C	and	VLDL‐C	clarified	that	the	methanolic	
extract	 of	A.	wilkesiana	 was	more	 effective	 than	 aqueous	 one	
which	realized	a	reduction	of	LDL‐C	and	VLDL‐C	in	10	and	24%,	
respectively	 [28].	 Moreover,	 the	 study	 of	 Odoh	 et	 al.,	 [32]	
indicated	that	a	significant	reduction	(p	<	0.05)	 in	serum	total	
cholesterol	 and	 triacylglycerol	 levels	 of	 50%	 and	 58%,	
respectively,	 was	 observed	 for	 the	 dose	 200	 mg/kg	 b.	 wt.	 of	
methanolic	 A.	 wilkesiana	 root	 extract	 in	 alloxan‐induced	
diabetic	rats.	The	beneficial	effects	of	methanolic	A.	wilkesiana	
leaves	extract	on	lipid	profile	of	diabetic	rats	could	be	related	to	
the	 insulinotropic	effect	or	 the	 insulin	secretagogue	activity	of	
this	 extract	 by	 its	 components,	 especially	 flavonoids,	 which	
significantly	 increased	 LDL	 receptor	 mRNA	 levels,	 which,	 in	
turn,	increase	hepatic	uptake	and	degradation	of	LDL	causing	a	
decrease	 in	 serum	 LDL	 levels,	 as	 well	 as	 its	 caroteinoides,	
which	are	thought	to	act	mainly	as	antioxidants	[39].	
	
3.6.	Effect	of	crude	methanolic	leaves	extracts	of	Acalypha	
wilkesiana	on	atherogenic	indices	
	
Atherogenic	 indices	 are	 powerful	 indicators	 of	 the	 risk	 of	
heart	 disease.	 The	 higher	 values	 of	 atherogenic	 indices	 are	 a	
sign	 of	 the	 higher	 risk	 of	 developing	 cardiovascular	 diseases	
[40].	On	the	other	hand,	low	atherogenic	indices	pointed	to	the	
protection	against	coronary	heart	diseases	[41].	
Clinical	 findings	 in	 Table	 6	 show	 the	 effect	 of	 crude	
methanolic	A.	wilkesiana	 leaves	extract	on	atherogenic	 indices	
in	 diabetic	 rats.	 It	 could	 be	 concluded	 that	 no	 significance	
differences	 in	 both	 cardiac	 risk	 ratio	 and	 atherogenic	
coefficient	between	normal	rats	and	diabetic	rats	administrated	
with	 the	 extract	 after	 30	 days.	 In	 addition,	 the	 results	 for	
atherogenic	 index	 of	 plasma	 appeared	 no	 significant	
differences	 in	 both	 normal	 and	 treated	 diabetic	 rats	 at	 all	
experimental	 periods.	 Our	 consequences	 for	 atherogenic	
indices	were	in	the	same	line	with	those	obtained	by	Ikewuchi	
et	al.,	 [28]	who	accomplished	that	no	significant	differences	in	
the	 atherogenic	 indices	 of	 the	 A.	 wilkesiana	 treated	 groups	
compared	with	control,	except	the	atherogenic	index	of	plasma	
which	 was	 significantly	 lower.	 In	 addition,	 these	 portends	
reductions	of	cardiovascular	risk,	according	to	clinical	data	as	a	
caused	 by	 raising	 of	 HDL‐C	 concentration	 in	 plasma	 [42].	
Furthermore,	 treated	 diabetic	 rats	 showed	 decrease	 in	
atherogenic	 index	 and	 increase	 in	 percentage	 of	 protection	
against	 atherogenicity.	 Our	 data	 reported	 that	 a	 decrease	 in	
atherogenic	index	is	due	to	an	increase	in	HDL‐C	levels	after	the	
treatment	 with	 plant	 extract.	 HDL‐C	 is	 known	 to	 play	 an	
important	 role	 in	 the	 transport	of	 cholesterol	 from	peripheral	
cells	 to	 the	 liver	 by	 a	 pathway	 termed	 reverse	 cholesterol	
transport,	and	is	considered	to	be	a	cardio	protective	lipid.	The	
existence	 of	 negative	 correlation	 between	 HDL‐C	 and	
atherosclerosis	 resulted	 in	 improvement	 in	 the	 percentage	 of	
protection	 against	 atherogenicity	 in	 STZ‐induced	 diabetic	
treated	 rats	 [43].	 Thus,	 the	 antihyperlipidemic	 effect	 of	
methanolic	A.	wilkesiana	 leaves	extract	could	play	a	protective	
role	 against	 the	 development	 of	 atherosclerosis	 and	
cardiovascular	complications	in	diabetes	mellitus.	
	
3.7.	Haematological	parameters	(complete	blood	count)	
	
The	 complete	 blood	 count	 (CBC)	 is	 used	 as	 a	 broad	
screening	test	to	check	for	such	disorders	as	anemia,	 infection	
and	 many	 other	 diseases.	 It	 is	 actually	 a	 panel	 of	 tests	 that	
examines	different	parts	of	the	blood,	which	play	an	important	
role	 in	metabolism	and	 important	 indicators	of	health	 in	both	
human	 or	 animals	 [44].	 The	 complete	 blood	 count	 (CBC)	
includes	the	following	tests.	
	
3.7.1.	Hemoglobin	(Hb)	
	
Hemoglobin	 (Hb)	was	measured	 to	 detect	 anemia	 and	 its	
severity.	 This	 is	 one	 of	 those	 tests	 that	will	 vary	 in	 reference	
ranges,	although	it	is	fair	to	say	that	values	around	or	less	than	
10	 g/dL	 are	 usually	 seen	 in	 patients	 with	 some	 signs	 or	
symptoms	of	anemia	such	as	shortness	of	breath	or	fatigue	and	
pallor	 [45].	 Our	 findings	 in	 Table	 7	 show	 a	 decrease	 in	
hemoglobin	levels	from	14.2	to	11.1	g/dL	by	the	injection	with	
STZ	 to	 induce	diabetes	mellitus.	Then,	 the	oral	administration	
of	methanloic	A.	wilkesiana	 leaves	extract	 in	doses	10,	20	and	
40	mg/100	g	b.	wt.	confirmed	a	non‐significant	dose‐dependent	
increase	in	hemoglobin	levels	to	reach	13.1,	13.6	and	15.0	g/dL,	
respectively	 at	 the	end	of	 the	experimental	period.	Therefore,	
the	 bioactive	 components	 in	methanloic	 extract	 healing	 effect	
on	disorders	of	anemia,	such	as	shortness	of	breath	and	pallor.		
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Table	8.	Effect	of	treatment	of	crude	methanol	leaves	extract	of	Acalypha	wilkesiana	on	levels	of	RBC	(106/µL)	and	RBC	indices	in	diabetic	rats	*.		
Treatment		
period	
Normal		
control		
Diabetic		
control		
Diabetic	+	
metformin	
Diabetic	+	A.	wilkesiana	extract	ata	dose:	
10	mg/100	g	b.	wt. 20	mg/100	g	b.	wt.	 40	mg/100	g	b.	wt.
RBC	(106/	µL)	 Zero	time	 8.33±0.24	 6.15±0.17 5.93±0.14 6.69±0.21 6.43±0.23	 6.83±0.30
30	days	 9.01±0.32	 5.92±0.15	a	 7.88±0.27	 8.02±0.34	 8.29±0.25	 8.69±0.19	
R
B
C	
in
di
ce
s	
HCT	(%)	 Zero	time	 46.9±1.57	 35.2±0.98	a 36.2±1.11	a 35.2±1.04	a 37.3±1.17	a	 37.7±1.14	a
30	days	 44.2±1.32	 30.0±0.89	a	 39.6±1.13	a,b	 43.7±1.36	b,c	 44.7±1.21	b,c	 45.1±1.54	b,c	
MCV	(µm3)	 Zero	time	 69±2.09	 36±1.14	a 39±1.11	a 31±0.88	a,c 38±1.21	a 33±0.99	a,c
30	days	 70±2.31	 33±1.11	a 51±1.45	a,b 67±2.01	b,c 68±2.14	b,c	 69±1.99	b,c
MCH	(pg)	 Zero	time	 20.7±0.77	 14.4±0.33	a 13.6±0.32	a 14.3±0.44	a 14.8±0.23	a	 15.2±0.42	a
30	days	 23.7±0.87	 13.3±0.27	a 16.9±0.32 20.0±0.76	a,b,c 20.4±0.87	a,b,c	 20.8±0.63	a,b,c
MCHC	(g/dL)	 Zero	time	 36.4±1.21	 22.7±0.76	a	 23.1±0.87	a	 26.2±0.45	a	 25.3±0.54	a	 25.7±0.74	a	
30	days	 36.1±1.14	 20.2±0.77	a 27.0±0.87	a,b 34.0±1.21	b,c 36.2±1.13	b,c	 36.6±1.14	b,c
RDW	(%)	 Zero	time	 20.7±0.64	 12.7±0.32	a	 12.6±0.24	a	 13.0±0.24	a	 12.9±0.35	a	 13.3±0.32	a	
30	days	 20.6±0.55	 13.1±0.28	a 16.4±0.35	a 16.2±0.36	a 17.9±0.35	a	 18.3±0.43	b
*	The	values	are	mean±SD	of	6	rats	in	each	group.		
a	Significantly	different	from	normal	control	at	p	<	0.05.	
b	Significantly	different	from	diabetic	control	at	p	<	0.05.	
c	Significantly	different	from	diabetic+metformin	at	p	<	0.05.	
	
	
Table	9.	Effect	of	treatment	of	crude	methanolic	leaves	extract	of	Acalypha	wilkesiana	on	levels	of	Plt	(103/µL)	and	Plt	indices	in	diabetic	rats	*.		
	 Treatment	
period	
Normal		
control		
Diabetic
control		
Diabetic	+	
metformin	
Diabetic	+	A.	wilkesiana	extract	at	a	dose	
10	mg/100	g	b.	wt. 10	mg/100	g	b.	wt.	 10	mg/100	g	b.	wt.
Plt	(103/	µL)	 Zero	time	 1072±33.11	 553±17.35	a 432±18.27	a,b 519±19.43	a,b,c 425±16.37	a,b	 501±20.58	a,b,c
30	days	 1100±41.16	 340±16.17	a	 787±28.22	a,b	 1000±38.55	a,b,c	 1008±36.88	a,b,c	 1050±42.56	a,b,c	
PL
T
	in
di
ce
s	
PCT	(%)	 Zero	time	 0.9±0.09	 0.33±0.03 0.42±0.04 0.34±0.02 0.36±0.02	 0.34±0.02
30	days	 0.9±0.08	 0.3±0.02 0.61±0.04 0.82±0.04 0.86±0.05	 0.88±0.06
MPV	(µm3)	 Zero	time	 9.7±0.33	 5.6±0.31	a	 5.3±0.19	a	 5.5±0.21	a	 5.8±0.28	a	 5.5±0.21	a	
30	days	 9.5±0.23	 5.9±0.32	a 7.1±0.21	a 8.7±0.31	b 9.9±0.34	b	 9.9±0.31b
PDW	(%)	 Zero	time	 14.6±0.55	 4.7±0.17	a	 5.2±0.21	a	 4.3±0.15	a	 4.4±0.21	a	 4.5±1.17	a	
30	days	 14.9±0.57	 4.8±0.14	a 9.2±0.32	a,b 12.3±0.34	a,b,c 13.4±0.28	b,c	 14.5±0.29	b,c
*	The	values	are	mean±SD	of	6	rats	in	each	group.		
a	Significantly	different	from	normal	control	at	p	<	0.05.	
b	Significantly	different	from	diabetic	control	at	p	<	0.05.	
c	Significantly	different	from	diabetic+metformin	at	p	<	0.05.	
	
	
These	 results	 for	hemoglobin	 levels	were	not	 agreed	with	
those	obtained	by	Ikewuchi	et	al.,	[28]	who	mentioned	that	no	
significant	 differences	 between	 normal	 and	 treated	 rats	 with	
aqueous	 A.	 wilkesiana	 leaves	 extract.	 Thus,	 extraction	 of	
bioactive	 compounds	with	methanol	 was	more	 effective	 than	
water	 to	 cure	 symptoms	 accomplished	 with	 hemoglobin	
decline	caused	by	diabetes	mellitus.	
	
3.7.2.	Red	blood	cells	(RBC)	
	
The	count	of	the	actual	number	of	red	blood	cells	(RBC)	per	
volume	 of	 blood.	 Both	 increase	 and	 decrease	 can	 point	 to	
abnormal	 conditions.	 Decreased	 count	 of	 RBC	 indices	 to	
anemia,	while	increasing	count	of	RBC	in	the	company	of	fluid	
loss	indices	to	diarrhea,	dehydration	and	burns	[44].	
Haematological	results	in	Table	8	illustrate	decrease	in	RBC	
count	 from	8.33	 to	6.15×	106/µL	by	 the	 injection	of	 rats	with	
STZ	 to	 induce	 diabetes.	 Then,	 methanloic	 leaves	 extract	 of	A.	
wilkesiana	 in	 doses	 10,	 20	 and	 40	mg/100g	 b.	wt.	 caused	 an	
increase	 in	 RBC	 reckon	 to	 reach	 8.02,	 8.29	 and	 8.69×106/µL,	
respectively	 after	 30	 days.	 From	 the	 same	 table,	 it	 could	 be	
noticed	 that	 RBC	 indices	 (HTC,	 MCV,	 MCH,	 MCHC	 and	 RDW)	
were	 reduced	 by	 the	 injection	 with	 streptozocin.	 Afterward,	
RBC	 indices	 were	 gradually	 increased	 to	 almost	 the	 normal	
control	 rat’s	 values	 by	 treatment	 with	 A.	 wilkesiana	 leaves	
extract.	 On	 the	 contrary,	 Ikewuchi	 et	 al.,	 [28]	 found	 no	
significant	 differences	 between	 normal	 and	 treated	 rats	 with	
aqueous	A.	wilkesiana	 leaves	 extract	 for	 both	RBCs	 count	 and	
RBC	 indices.	 This	 gives	 an	 indication	 that	 the	 methanloic	 A.	
wilkesiana	 leaves	 extract	 may	 contain	 some	 phytochemicals	
that	can	stimulate	the	formation	or	secretion	of	erythropoietin	
in	the	stem	cells	of	the	animals.	Erythropoietin	is	a	glycoprotein	
hormone	which	 stimulates	 stem	 cells	 in	 the	 bone	marrow	 to	
produce	 red	blood	cells	 [46].	The	stimulation	of	 this	hormone	
enhances	 rapid	 synthesis	 of	 RBC	 which	 is	 supported	 by	 the	
improved	 level	 of	 MCH	 and	 MCHC	 [47].	 Moreover,	 Table	 1	
indicates	 the	 presence	 of	 flavonoids,	 tannins,	 phenols	 and	
flavonols	 in	 methanloic	 A.	 wilkesiana	 leaves	 extract.	 These	
compounds	have	been	 reported	 to	possess	 strong	 antioxidant	
capacity,	 therefore,	 could	 inhibit	 the	 peroxidation	 of	
polyunsaturated	 fatty	 acids	 in	 the	 cell	 membrane	 and	
haemolysis	of	red	blood	cells	in	the	diabetic	animals.	
	
3.7.3.	Platelets	(Plt)	
	
Platelets	 (Plt)	 are	 produced	 within	 the	 vascular	 channels	
(sinusoids)	 of	 the	 bone	 marrow	 by	 the	 fragmentation	 of	 the	
protruding	 cytoplasm	 of	 large	 bone	 marrow	 cells	 known	 as	
megakaryocytes.	Platelets	count	and	its	indices	(PCT,	MPV	and	
PDW)	levels	were	reduced	to	reach	about	50%	of	these	values	
in	normal	rats	when	streptozocin	was	used	to	 induce	diabetes	
mellitus.	 Then,	 the	 oral	 administration	 of	 methanoic	 A.	
wilkesiana	 leaves	extract	established	dose‐dependent	 increase	
in	 platelet	 counts	 and	 its	 indices	 to	 achieve	 the	 highest	
percentage	levels	(about	90%)	compared	with	diabetic	rats	at	a	
dose	of	40	mg/100	b.	wt.	at	the	end	of	the	experimental	period	
as	shown	in	Table	9.	
Our	 findings	 were	 in	 accordance	 with	 those	 obtained	 by	
Ikewuchi	et	al.,	[28]	who	calculated	the	increasing	percentages	
of	 platelet	 counts	 to	 reach	 about	 94,	 57	 and	 31%	 of	 treated	
diabetic	rats	with	aqueous	A.	wilkesiana	leaves	extract	at	doses	
10,	20	and	30	mg/100	g	b.	wt.,	respectively.	These	increasing	in	
platelets	 count	 and	 its	 indices	 imply	 the	 increase	 in	 clotting,	
which	protect	against	bleeding	and	 increase	 insulin	resistance	
as	the	cause	of	predisposition	to	adverse	cardiovascular	events.	
Taniguchi	 et	 al.,	 [48]	 reported	 that	 increased	 platelets	 count	
may	independently	predict	insulin	resistance	among	non	obese	
type	 2	 diabetes	 mellitus	 patients.	 This	 effect	 indicated	 the	
ability	 of	 the	 methanoic	 A.	 wilkesiana	 leaves	 extract	 to	
stimulate	 the	 biosynthesis	 of	 clotting	 factors	 due	 to	 the	
presence	 of	 active	 compounds	 that	 might	 help	 to	 precipitate	
blood	coagulation	or	clotting,	especially	during	severe	bleeding	
or	haemorrhage	[49].	
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Table	10.	Effect	of	treatment	of	crude	methanolic	leaves	extract	of	Acalypha	wilkesiana	on	levels	of	WBC	(103/µL)	and	WBC	differential	in	diabetic	rats	*.		
	 Treatment	
period	
Normal		
control		
Diabetic	
control		
Diabetic	+	
metformin	
Diabetic	+	A.	wilkesiana	extract	at	adose	
10	mg/100	g	b.	wt 10	mg/100	g	b.	wt	 10	mg/100	g	b.	wt
WBC	(103/	µL)	 Zero	time	 6.5±0.43	d	 11.5±0.66	a	 12.1±0.65	a	 11.7±0.56	a	 11.9±0.	54	a	 11.5±0.55	a	
30	days	 5.9±0.21	d	 12.0±0.45	a 9.2±0.32	a,b 7.3±0.43	b 6.6±0.31b,c	 6.5±0.31	b,c
W
B
C	
di
ff
er
en
ti
al
	
LYM	(%)	 Zero	time	 58.4±2.13	c	 66.1±2.43	a 69.4±2.22	a 68.5±2.87	a 67.3±2.76	a	 67.0±2.42	a
30	days	 51.7±2.09	d	 75.3±2.54	a	 60.1±1.89	 51.5±2.03	 53.1±2.11	b,c	 52.7±1.99	b,c	
MON	(%)	 Zero	time	 1.3±0.02	a	 1.9±0.09	a 1.8±0.08 1.1±0.07	b 1.0±0.08	b	 1.2±0.08	b
30	days	 1.9±0.03	a	 1.3±0.09	a 1.0±0.09	a 1.1±0.01	a 1.8±0.31	c	 1.7±0.31	c
GRA	(%)	 Zero	time	 40.3±0.25	c	 32.0±0.31	a 28.8±0.17	a,b 30.4±0.21	a,c 31.7±0.19	a,c	 31.8±0.21	a,c
30	days	 46.4±1.11	a	 23.4±0.76	a	 38.9±0.65	a,b	 48.4±0.45	b,c	 45.9±0.64	b,c	 45.6±0.65	b,c	
*	The	values	are	mean±SD	of	6	rats	in	each	group.	
a	Significantly	different	from	normal	control	at	p	<	0.05.	
b	Significantly	different	from	diabetic	control	at	p	<	0.05.	
c	Significantly	different	from	diabetic	+	metformin	at	p	<	0.05.	
	
	
3.7.4.	White	blood	cells	(WBC)	
	
White	blood	cells	(WBC)	were	primarily	formed	in	the	bone	
marrow	and	may	also	be	produced	 in	organs	of	 the	 lymphatic	
system	such	as	spleen,	thymus	and	lymph	nodes.	They	serve	to	
fight	off	infections	and	protect	the	body	from	diseases.	This	test	
serves	 to	 monitor	 diseases	 progression	 and/or	 response	 to	
chemotherapy.	 Moreover,	 the	 differential	 divided	 the	 various	
types	 of	 white	 blood	 cells	 based	 on	 size	 distribution.	 The	
differential	is	done	to	evaluate	the	body’s	capacity	to	resist	and	
overcome	 infection	 [45].	 Quantifiable	 findings	 in	 Table	 10	
explain	the	effect	of	streptozocin	 injection	of	white	blood	cells	
and	its	indices	(LYM,	MON	and	GRA	which	include	neutrophils,	
eosinophils,	and	basophils).	Drug	poisoning	is	one	of	the	main	
causes	of	raising	white	blood	cell	count,	which	plays	important	
roles	 in	 the	 destabilization	 of	 coronary	 artery	 plaques	 at	 the	
onset	of	acute	 coronary	syndrome	 [50].	However,	 an	elevated	
white	 blood	 cell	 count	 in	 peripheral	 blood	 is	 a	 known	 risk	
factor	 of	 coronary	 artery	 disease	 [51].	 Thus,	 the	 observed	
higher	white	 blood	 cell	 count	 for	 diabetic	 rats	 suggestion	 the	
protection	 against	 onset	 of	 acute	 coronary	 syndrome	 and	 the	
increased	 risk	 of	 coronary	 artery	 disease.	 On	 the	 other	 hand,	
the	 white	 blood	 cell	 counts	 and	 its	 related	 indices	 were	
significantly	 restored	 to	 near	 normal	 after	 methanolic	 A.	
wilkesiana	 leaves	 extract	 administration	 at	 doses	 20	 and	 40	
mg/100	g	b.	wt.	The	presence	of	some	phytochemicals	in	the	A.	
wilkesiana	 leaves	 extract	 with	 the	 ability	 to	 stimulate	 the	
production	of	white	blood	count	and	 its	differentials	 could	be	
responsible	for	the	observed	results	in	the	treated	diabetic	rats.	
This	observation	of	increasing	levels	of	these	parameters	by	A.	
wilkesiana	 extract	 suggests	 that	 the	 principal	 function	 of	
phagocytes,	 which	 is	 to	 defend	 against	 invading	
microorganisms	 by	 ingesting	 and	 destroying	 them,	 thus	
contributing	to	cellular	inflammatory	processes	of	the	animals,	
will	be	enhanced	[52].	
	
4.	Conclusion	
	
In	 conclusion,	 this	 investigation	 revealed	 the	 presence	 of	
pharmacologically	active	compounds	in	the	methanoilc	extract	
of	 Acalypha	wilkesiana	 leaves.	 This	 extract	 had	 hypoglycemic	
activities	and	positively	affected	on	 the	hematopoietic	system,	
the	 integrity	 of	 liver	 and	 kidney	 functions	 and	 improved	 the	
lipid	profile	as	a	cardioprotective	agent	for	STZ	treated	diabetic	
rats.	 Furthermore,	 extract	 had	 no	 deleterious	 effect	 on	
hemoglobin	 or	 red	 blood	 cell	 morphology.	 All	 of	 these	
highlights	 of	 methanolic	 Acalypha	 wilkesiana	 leaves	 extract	
support	 its	 uses	 as	 a	 potential	 source	 of	 discovery	 for	 new	
therapeutic	agents	for	health	care	and	management	of	diabetes	
mellitus	and	its	complications.	
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